DOCSLIB.ORG

Table 1 List of Genes Expressed Highly in TS6.5 Cells Average Expression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table 1 List of Genes Expressed Highly in TS6.5 Cells Average Expression Table 1 List of genes expressed highly in TS6.5 cells Average Expression Level Clone Name Putative Identification Fold Difference ES cells TS6.5 cells H3020C07 eHAND >100 13500 9741200 H3021C07 Mouse serine protease inhibitor 6 (Spi6) >100 0 134700 H3129F11 Unknown >100 0 73400 H3138C09 Human putative cDNA clone 48 10500 506500 H3137C06 Mouse transglutaminase (TGase) 43 42100 1827100 H3020E07 Unknown 41 6800 278800 H3008D11 Mouse placental lactogen I (PL-I) 26 4200 109800 H3073E07 Unknown 25 11800 299100 H3153E01 Unknown 24 18300 446700 H3014H12 Mouse Endo A cytokeratin 23 41300 944200 H3007D03 Mouse embryonal Fyn-associated substrate (Efs) 22 30100 653100 H3036G12 Mouse cytokeratin Endo A 17 293600 5089500 H3159G03 Unknown 16 124000 1991300 H3032H02 Mouse phosphatidylcholine transfer protein-like (Pctpl) 16 72100 1151900 H3051A06 Unknown 15 14700 222300 H3007G06 Mouse EndoB cytokeratin 15 278100 4138600 H3108A05 Mouse p53 tumor suppressor 15 30000 439200 H3014F05 Mouse S100 calcium-binding protein A13 (S100a13) 14 39600 555800 H3018E05 Mouse Endo A cytokeratin 13 367900 4920100 H3108A04 Mouse sulfated glycoprotein-2 isoform 1/clustrin precursor 13 89600 1137700 H3014E10 Mouse transcription factor AP-2 gamma (Tcfap2c) 12 80600 970400 H3021B02 Mouse cytokeratin (endoB) gene 12 204500 2398800 H3095H12 Mouse carbonic anhydrase 4 (Car4) 11 17100 193300 H3138E02 Mouse collagen alpha-2(IV) 11 61600 694900 H3132A03 Unknown 11 144800 1607700 H3010B01 Human ATP citrate lyase (ACLY) 11 29300 322200 H3108A01 Mouse DnaQL protein (Dnaql) 11 29100 319000 H3143E11 Unknown 11 12600 135000 H3014E12 Human signal recognition particle 72kD 10 41400 434400 H3108A03 Mouse small intestine apolipoprotein B -editing component 1 (Apobec1) 10 21600 215200 H3016C05 Mouse annexin A5 (Anxa5) 9.9 96400 959000 H3041A06 Unknown 9.6 70000 673800 H3134D04 Mouse hexokinase 9.6 214000 2054400 H3027G05 Mouse placentae and embryos oncofetal gene (Pem) 9.5 485900 4598000 H3001A02 Mouse secretin (Sct) 9.2 17500 160800 H3056A10 Human polyadenylate binding protein-interacting protein 1 9.2 60800 558500 H3031C01 Mouse EndoA cytokeratin 9.1 170600 1556300 H3129H09 Mouse tissue factor pathway inhibitor (TFPI) initiation of coagulation by factor Xa inhibition 8.9 59800 530500 H3159G06 Mouse alpha-1 type IV collagen (Col4a-1) 8.8 267800 2348300 H3003C04 Unknown 8.3 34700 289100 H3001A08 Mouse myosin Ib (Myo1b) 8.0 16700 133800 H3052B04 Unknown 8.0 22000 175500 H3020H11 Unknown 7.3 19000 138400 H3017E03 Unknown 7.2 16700 120600 H3014C06 Mouse beta-2 microglobulin (B2m) 7.2 236500 1698200 H3014G12 Mouse ubiquitin conjugating enzyme 2e (Ubc2e) 7.1 82200 587600 H3018C05 Unknown 7.0 24700 172000 H3076B01 Mouse melanocyte-specific gene 1 (msg1) 6.8 11700 80100 H3006A12 Unknown 6.5 1792000 11721800 H3040B03 Mouse solute carrier family 9 (sodium/hydrogen exchanger) 3 regulator 1 (Slc9a3r1) 6.4 123500 791500 H3147D07 Unknown 6.4 16500 105000 H3031G08 Putative human monocarbocylate transporter 6 6.3 53300 333500 H3009F04 Mouse GATA-binding protein 2 (Gata2) 6.3 27000 168800 H3014F12 Unknown 6.2 101300 631100 H3001E07 Unknown 6.2 1111800 6902500 H3005A12 Human cDNA FLJ10366 fis 6.0 941600 5678100 H3006B12 Putative klepn transcriptional regulator LTRA 6.0 675300 4037800 H3090H10 Unknown 5.9 40200 235500 H3007B05 Human cDNA FLJ22228 fis 5.8 17200 100000 H3018G06 Unknown 5.8 194300 1129600 H3094G12 Unknown 5.8 64700 372600 H3094F12 Mouse v-ral simian leukemia viral oncogene homolog B (ras related) (Ralb) 5.7 53600 306100 H3038B03 Unknown 5.6 21100 119100 H3053B10 Unknown 5.6 27800 156300 H3001G07 Human cDNA DKFZp434P176 (from clone DKFZp434P176) 5.5 51700 286500 H3104D07 Mouse mammary-derived growth inhibitor (MDGI)/ fatty acid-binding protein 5.5 357900 1970900 H3005B12 Unknown 5.5 1424500 7805300 H3021G01 Unknown 5.5 53600 293400 H3051A08 Human cDNA FLJ12984 fis 5.1 24300 124500 H3104F03 Rat potassium channel regulator 1 5.1 228400 1160900 H3029A03 Mouse peroxisomal trans 2-enoyl CoA reductase 5.1 29400 148500 H3134A07 Unknown 5.0 19600 97600 H3029A04 Mouse SCIP myelin-specific POU-domain transcriptional repressor 4.9 191600 947600 H3110C09 Rat plectin 4.9 133100 652800 H3129D02 Mouse mSin3B 4.9 92100 451100 H3051C08 Unknown 4.9 27000 131700 H3019H02 Unknown 4.9 122900 599300 H3146F05 Unknown 4.8 59300 285700 H3142E08 Unknown 4.8 21200 101500 H3006A11 Mouse 7-dehydrocholesterol reductase 4.7 895400 4217800 H3096D09 Mouse phosphatidylinositol transfer protein (Pitpn) 4.7 102400 481600 H3137B05 Mouse ELAC1 (Elac1) 4.7 14700 69100 H3001E05 Mouse homer-2b 4.6 62700 285600 H3020E06 Unknown 4.5 57800 259000 H3029A02 Mouse selective hybridizing clone (Shyc) expressed in nervous system 4.5 149100 664100 H3039G06 Unknown 4.4 123200 548200 H3002C07 Mouse skeletal muscle beta tropomyosin 4.4 87300 382700 H3133C01 Mouse Sui1 4.4 575600 2519500 H3105C10 Mouse LIMK2b 4.4 39800 174000 H3151A03 Unknown 4.3 111400 475600 H3007C12 Unknown 4.2 126300 532400 H3052A10 Unknown 4.2 53000 221400 H3004G01 Unknown 4.2 95500 398600 H3049A10 Unknown 4.1 35700 147600 H3052D04 Mouse mitocondra genome 4.1 102800 424700 H3151A02 Unknown 4.1 236700 973400 H3050H04 Mouse 18S rRNA gene clones 5a67 4.1 31700 130100 H3108G04 Mouse cysteine rich intestinal protein (Crip) 4.1 121400 496500 H3052C04 Human APG5 (autophagy 5 S. cerevisiae)-like 4.1 74800 305000 H3020C05 Human putative cDNA clone 4.0 68200 275400 H3039E06 Unknown 4.0 1106500 4398400 H3012C06 Mouse scavenger receptor class B type I (mSR-BI)/ High density lipoprotein receptor 4.0 126700 501400 H3039G05 Mouse erythroid differentiation regulator inducing hemoglobin synthesis 4.0 2416000 9551900 H3018F06 Unknown 3.9 153700 600600 H3132B06 Unknown 3.9 16386100 63923700 H3101E04 Human putative cDNA clone 3.9 81700 318700 H3129D09 Human cDNA clone 3.9 73200 283800 H3134G08 Unknown 3.9 151900 586900 H3069B09 Human cDNA DKFZp761L1216 (from clone DKFZp761L1216) 3.9 53800 207800 H3151F11 Unknown 3.8 53400 204100 H3133B01 Human cDNA FLJ21799 fis 3.8 348100 1316400 H3051H03 Mouse TBX1/ LPS-induced TNF-alpha factor LITAF 3.8 35300 133100 H3146C11 Mouse evectin-2 (Evt2) 3.7 46600 173100 H3039C06 Unknown 3.6 108300 394800 H3146H06 Human CTL2 gene 3.6 117300 423600 H3137E10 Mouse testis specific 2P1 protein 3.6 138300 496300 H3008A10 Mouse MYB binding protein (P160) 1a (Mybbp1a) 3.5 244800 865400 H3008F08 Mouse eIF-1A (eIF-1A) 3.5 530200 1867400 H3039G04 Mouse seryl-tRNA synthetase 3.5 2382000 8388100 H3039E05 Unknown 3.5 205400 720100 H3027D05 Mouse thymic shared antigen-1 (TSA-1) 3.5 104900 366300 H3009H12 Unknown 3.5 106000 369900 H3148C08 Unknown 3.5 98100 342200 H3137G02 Rat gis5 glucocorticoid-inducible protein 3.5 2150200 7492200 H3130D09 Unknown 3.5 1878800 6486700 H3010G06 Unknown 3.4 307000 1055400 H3009C06 Human BRCA2 region sequence CG037 3.4 815600 2800800 H3122C11 Unknown 3.4 171000 587100 H3052A11 Unknown 3.4 82800 282500 H3137A03 Mouse integrin alpha 3A 3.4 122300 416100 H3108B03 Unknown 3.4 47200 159800 H3103E01 Mouse topoisomerase 3 alpha (Top3a) 3.4 40300 136300 H3137B06 Mouse ornithine aminotransferase 3.4 46700 157800 H3050C10 Unknown 3.4 178800 602100 H3008A08 Mouse maternal embryonic leucine zipper kinase (Melk) 3.4 226900 763300 H3017H10 Unknown 3.4 220300 740100 H3050A11 Unknown 3.3 48300 161800 H3073G07 Mouse granzyme M 3.3 70300 235400 H3134D06 Unknown 3.3 34400 114700 H3014G07 Mouse phosphoprotein enriched in astrocytes 15 (Pea15) 3.3 62800 209200 H3133D01 Mouse deoxyribonuclease II (Dnase2) 3.3 56100 186400 H3142B05 Unknown 3.3 177500 589700 H3021B06 Unknown 3.3 712300 2355000 H3052C08 Mouse coproporphyrinogen oxidase (Cpo) 3.3 45100 148400 H3006H06 Mouse calmodulin synthesis (CaM) cDNA 3.3 252100 828200 H3039B06 Mouse DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 19 3.3 49400 161300 H3039D06 Unknown 3.3 146500 477900 H3020C06 Mouse thymoma viral proto-oncogene (Akt) 3.2 107200 348200 H3035A12 Unknown 3.2 133100 431000 H3012A06 Mouse placental lactogen I (PL-I) 3.2 89400 288400 H3001E09 Mouse full length insert cDNA clone EUROIMAGE 441571 3.2 119500 380700 H3002E04 Unknown 3.2 109800 349000 H3132A06 Mouse alcohol dehydrogenase family 1 subfamily A7 (Aldh1a7) 3.2 1799800 5713400 H3128F10 Human ADP-ribosylation factor binding protein GGA3 3.2 31300 99200 H3013C04 Mouse Oxydative stress induced 3.2 1907100 6038600 H3039G03 Unknown 3.2 678500 2144800 H3132H09 Unknown 3.1 84800 264400 H3150E11 Human cDNA FLJ22293 fis 3.1 45500 140000 H3006A09 Mouse 45S pre rRNA gene 3.1 96300 296100 H3158G06 Mouse erythroid differentiation regulator inducing hemoglobin synthesis 3.1 1076700 3302500 H3142H03 Unknown 3.1 44200 135400 H3006C02 Putative protease inhibitor 3.1 168600 516200 H3014A12 Mouse Mbh1 gelsolin-like actin filament capping protein 3.1 154000 470600 H3039E07 Human isocitrate dehydrogenase 3 (NAD+) beta (IDH3B) 3.0 244300 743600 H3009A06 Human Arginine-rich protein 3.0 291300 886400 H3017A12 Mouse synaptogyrin 1 (Syngr1) 3.0 130000 392500 H3133C05 Unknown 3.0 296700 895600 H3005B11 Unknown 3.0 131000 395400 H3039E08 Mouse SH3-containing protein SH3P2 3.0 86500 260900 H3049G07 Mouse PGES prostaglandin E synthase 3.0 64100 193100 H3142E10 Unknown 3.0 22200 66500 H3018H02 Mouse tubulin beta-3 3.0 185300 551700 H3134A05 Unknown 3.0 646100 1912000 H3127H03 Putative mouse ribosomal protein L34 3.0 1030700 3049600 H3003F12 Mouse BiP kinship with the 70-kDa heat shock protein family 3.0 107100 316600 H3137F10 Unknown 2.9 96200 282600 H3007A12 Unknown 2.9 111500 327400 H3132D06 Unknown 2.9 825900 2423200 H3084E06 Human putative cDNA clone 2.9 188100 549700
Load more

Recommended publications
  • CRISPR Screening of Porcine Sgrna Library Identifies Host Factors
    ARTICLE https://doi.org/10.1038/s41467-020-18936-1 OPEN CRISPR screening of porcine sgRNA library identifies host factors associated with Japanese encephalitis virus replication Changzhi Zhao1,5, Hailong Liu1,5, Tianhe Xiao1,5, Zichang Wang1, Xiongwei Nie1, Xinyun Li1,2, Ping Qian2,3, Liuxing Qin3, Xiaosong Han1, Jinfu Zhang1, Jinxue Ruan1, Mengjin Zhu1,2, Yi-Liang Miao 1,2, Bo Zuo1,2, ✉ ✉ Kui Yang4, Shengsong Xie 1,2 & Shuhong Zhao 1,2 1234567890():,; Japanese encephalitis virus (JEV) is a mosquito-borne zoonotic flavivirus that causes ence- phalitis and reproductive disorders in mammalian species. However, the host factors critical for its entry, replication, and assembly are poorly understood. Here, we design a porcine genome-scale CRISPR/Cas9 knockout (PigGeCKO) library containing 85,674 single guide RNAs targeting 17,743 protein-coding genes, 11,053 long ncRNAs, and 551 microRNAs. Subsequently, we use the PigGeCKO library to identify key host factors facilitating JEV infection in porcine cells. Several previously unreported genes required for JEV infection are highly enriched post-JEV selection. We conduct follow-up studies to verify the dependency of JEV on these genes, and identify functional contributions for six of the many candidate JEV- related host genes, including EMC3 and CALR. Additionally, we identify that four genes associated with heparan sulfate proteoglycans (HSPGs) metabolism, specifically those responsible for HSPGs sulfurylation, facilitate JEV entry into porcine cells. Thus, beyond our development of the largest CRISPR-based functional genomic screening platform for pig research to date, this study identifies multiple potentially vulnerable targets for the devel- opment of medical and breeding technologies to treat and prevent diseases caused by JEV.
    [Show full text]
  • Promiscuity and Specificity of Eukaryotic Glycosyltransferases
    Biochemical Society Transactions (2020) 48 891–900 https://doi.org/10.1042/BST20190651 Review Article Promiscuity and specificity of eukaryotic glycosyltransferases Ansuman Biswas and Mukund Thattai Simons Centre for the Study of Living Machines, National Centre for Biological Sciences, TIFR, Bangalore, India Correspondence: Mukund Thattai ([email protected]) Glycosyltransferases are a large family of enzymes responsible for covalently linking sugar monosaccharides to a variety of organic substrates. These enzymes drive the synthesis of complex oligosaccharides known as glycans, which play key roles in inter-cellular interac- tions across all the kingdoms of life; they also catalyze sugar attachment during the syn- thesis of small-molecule metabolites such as plant flavonoids. A given glycosyltransferase enzyme is typically responsible for attaching a specific donor monosaccharide, via a spe- cific glycosidic linkage, to a specific moiety on the acceptor substrate. However these enzymes are often promiscuous, able catalyze linkages between a variety of donors and acceptors. In this review we discuss distinct classes of glycosyltransferase promiscuity, each illustrated by enzymatic examples from small-molecule or glycan synthesis. We high- light the physical causes of promiscuity, and its biochemical consequences. Structural studies of glycosyltransferases involved in glycan synthesis show that they make specific contacts with ‘recognition motifs’ that are much smaller than the full oligosaccharide sub- strate. There is a wide range in the sizes of glycosyltransferase recognition motifs: highly promiscuous enzymes recognize monosaccharide or disaccharide motifs across multiple oligosaccharides, while highly specific enzymes recognize large, complex motifs found on few oligosaccharides. In eukaryotes, the localization of glycosyltransferases within compartments of the Golgi apparatus may play a role in mitigating the glycan variability caused by enzyme promiscuity.
    [Show full text]
  • Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
    www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • SUPPLEMENTARY MATERIAL Effect of Next
    SUPPLEMENTARY MATERIAL Effect of Next-Generation Exome Sequencing Depth for Discovery of Diagnostic Variants KKyung Kim1,2,3†, Moon-Woo Seong4†, Won-Hyong Chung3, Sung Sup Park4, Sangseob Leem1, Won Park5,6, Jihyun Kim1,2, KiYoung Lee1,2*‡, Rae Woong Park1,2* and Namshin Kim5,6** 1Department of Biomedical Informatics, Ajou University School of Medicine, Suwon 443-749, Korea 2Department of Biomedical Science, Graduate School, Ajou University, Suwon 443-749, Korea, 3Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea, 4Department of Laboratory Medicine, Seoul National University Hospital College of Medicine, Seoul 110-799, Korea, 5Department of Functional Genomics, Korea University of Science and Technology, Daejeon 305-806, Korea, 6Epigenomics Research Center, Genome Institute, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea http//www. genominfo.org/src/sm/gni-13-31-s001.pdf Supplementary Table 1. List of diagnostic genes Gene Symbol Description Associated diseases ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 Intrahepatic cholestasis ABCD1 ATP-binding cassette, sub-family D (ALD), member 1 Adrenoleukodystrophy ACVR1 Activin A receptor, type I Fibrodysplasia ossificans progressiva AGL Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase Glycogen storage disease ALB Albumin Analbuminaemia APC Adenomatous polyposis coli Adenomatous polyposis coli APOE Apolipoprotein E Apolipoprotein E deficiency AR Androgen receptor Androgen insensitivity
    [Show full text]
  • Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment
    microorganisms Review Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment Gregory Mathez and Valeria Cagno * Institute of Microbiology, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland; [email protected] * Correspondence: [email protected] Abstract: The first step of viral infection requires interaction with the host cell. Before finding the specific receptor that triggers entry, the majority of viruses interact with the glycocalyx. Identifying the carbohydrates that are specifically recognized by different viruses is important both for assessing the cellular tropism and for identifying new antiviral targets. Advances in the tools available for studying glycan–protein interactions have made it possible to identify them more rapidly; however, it is important to recognize the limitations of these methods in order to draw relevant conclusions. Here, we review different techniques: genetic screening, glycan arrays, enzymatic and pharmacological approaches, and surface plasmon resonance. We then detail the glycan interactions of enterovirus D68 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighting the aspects that need further clarification. Keywords: attachment receptor; viruses; glycan; sialic acid; heparan sulfate; HBGA; SARS-CoV-2; EV-D68 Citation: Mathez, G.; Cagno, V. Viruses Like Sugars: How to Assess 1. Introduction Glycan Involvement in Viral This review focuses on methods for assessing the involvement of carbohydrates in Attachment. Microorganisms 2021, 9, viral attachment and entry into the host cell. Viruses often bind to entry receptors that are 1238. https://doi.org/10.3390/ not abundant on the cell surface; to increase their chances of finding them, they initially microorganisms9061238 bind to attachment receptors comprising carbohydrates that are more widely expressed.
    [Show full text]
  • Supplementary Materials and Tables a and B
    SUPPLEMENTARY MATERIAL 1 Table A. Main characteristics of the subset of 23 AML patients studied by high-density arrays (subset A) WBC BM blasts MYST3- MLL Age/Gender WHO / FAB subtype Karyotype FLT3-ITD NPM status (x109/L) (%) CREBBP status 1 51 / F M4 NA 21 78 + - G A 2 28 / M M4 t(8;16)(p11;p13) 8 92 + - G G 3 53 / F M4 t(8;16)(p11;p13) 27 96 + NA G NA 4 24 / M PML-RARα / M3 t(15;17) 5 90 - - G G 5 52 / M PML-RARα / M3 t(15;17) 1.5 75 - - G G 6 31 / F PML-RARα / M3 t(15;17) 3.2 89 - - G G 7 23 / M RUNX1-RUNX1T1 / M2 t(8;21) 38 34 - + ND G 8 52 / M RUNX1-RUNX1T1 / M2 t(8;21) 8 68 - - ND G 9 40 / M RUNX1-RUNX1T1 / M2 t(8;21) 5.1 54 - - ND G 10 63 / M CBFβ-MYH11 / M4 inv(16) 297 80 - - ND G 11 63 / M CBFβ-MYH11 / M4 inv(16) 7 74 - - ND G 12 59 / M CBFβ-MYH11 / M0 t(16;16) 108 94 - - ND G 13 41 / F MLLT3-MLL / M5 t(9;11) 51 90 - + G R 14 38 / F M5 46, XX 36 79 - + G G 15 76 / M M4 46 XY, der(10) 21 90 - - G NA 16 59 / M M4 NA 29 59 - - M G 17 26 / M M5 46, XY 295 92 - + G G 18 62 / F M5 NA 67 88 - + M A 19 47 / F M5 del(11q23) 17 78 - + M G 20 50 / F M5 46, XX 61 59 - + M G 21 28 / F M5 46, XX 132 90 - + G G 22 30 / F AML-MD / M5 46, XX 6 79 - + M G 23 64 / M AML-MD / M1 46, XY 17 83 - + M G WBC: white blood cell.
    [Show full text]
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
    [Show full text]
  • Glycan Metabolism a Validated Grna Library for CRISPR/Cas9
    Glycobiology, 2018, vol. 28, no. 5, 295–305 doi: 10.1093/glycob/cwx101 Advance Access Publication Date: 5 January 2018 Original Article Glycan Metabolism A validated gRNA library for CRISPR/Cas9 targeting of the human glycosyltransferase Downloaded from https://academic.oup.com/glycob/article-abstract/28/5/295/4791732 by guest on 08 October 2018 genome Yoshiki Narimatsu2,3,1, Hiren J Joshi2, Zhang Yang2,3, Catarina Gomes2,4, Yen-Hsi Chen2, Flaminia C Lorenzetti 2, Sanae Furukawa2, Katrine T Schjoldager2, Lars Hansen2, Henrik Clausen2, Eric P Bennett2,1, and Hans H Wandall2 2Copenhagen Center for Glycomics, Departments of Cellular and Molecular Medicine and Odontology, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark, 3GlycoDisplay Aps, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark, and 4Instituto de Investigação e Inovação em Saúde,i3S; Institute of Molecular Pathology and Immunology of University of Porto, Ipatimup, Rua Júlio Amaral de Carvalho, 45, Porto 4200-135, Portugal 1To whom correspondence should be addressed: Tel: +45-35335528; Fax: +45-35367980; e-mail: [email protected] (Y.N.); Tel: +4535326630; Fax: +45-35367980; e-mail: [email protected] (E.P.B.) Received 25 September 2017; Revised 20 November 2017; Editorial decision 5 December 2017; Accepted 7 December 2017 Abstract Over 200 glycosyltransferases are involved in the orchestration of the biosynthesis of the human glycome, which is comprised of all glycan structures found on different glycoconjugates in cells. The glycome is vast, and despite advancements in analytic strategies it continues to be difficult to decipher biological roles of glycans with respect to specific glycan structures, type of glycoconju- gate, particular glycoproteins, and distinct glycosites on proteins.
    [Show full text]
  • Hereditary Multiple Exostoses (EXT1 & EXT2 Concurrently) Sequencing
    Lab Dept: Anatomic Pathology Test Name: HEREDITARY MULTIPLE EXOSTOSES (EXT1 & EXT2 CONCURRENTLY) SEQUENCING General Information Lab Order Codes: EX12 Synonyms: Exostoses 1 and 2; Hereditary multiple osteochondromata; Multiple cartilaginous exostoses; Diaphyseal aclasis; HME CPT Codes: 81479 x4 – Molecular Pathology Unlisted procedure Test Includes: Using genomic DNA obtained from the submitted specimen, bi-directional sequence of all 11 coding exons of the EXT1 gene is obtained and analyzed. Concurrently, targeted array CGH analysis with exon-level resolution (ExonArrayDx) is performed to evaluate for a deletion or duplication of one or more exons in both the EXT1 and EXT2 genes. Mutations found in the first person of a family to be tested are confirmed by repeat analysis using sequencing, restriction fragment analysis, or other appropriate method. Logistics Test Indications: Individuals with HME often develop benign cartilage-capped tumors (exostoses) at the ends of the long bones or the surface of flat bones. Exostoses develop prior to skeletal maturity only. Bony deformity, bowing of the long bones, limited range of motion, and premature osteoarthrosis may be associated with hereditary multiple exostoses (HME). Exostoses also may cause complications by putting pressure on nearby tissues, nerves or blood vessels. A rare but severe risk in patients with mutiples exostoses is the development of malignant chondrosarcoma, which in 1-5% of patients. Mutation in the EXT1 gene seems to be associated with a more severe disease and higher risk of developing chondrosarcoma than EXT2 mutations. Reasons for referral: 1. Confirmation of a clinical diagnosis 2. Genetic counseling Lab Testing Sections: Anatomic Pathology - Sendouts Referred to: GeneDx, Inc.
    [Show full text]
  • The Putative Tumor Suppressors EXT1 and EXT2 Form a Stable Complex That Accumulates in the Golgi Apparatus and Catalyzes the Synthesis of Heparan Sulfate
    The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate Craig McCormick, Gillian Duncan, K. Tina Goutsos, and Frank Tufaro* Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada Edited by Kai Simons, European Molecular Biology Laboratory, Heidelberg, Germany, and approved November 19, 1999 (received for review August 23, 1999) Hereditary multiple exostoses, a dominantly inherited genetic raised by these observations. EXT1, when overexpressed in a disorder characterized by multiple cartilaginous tumors, is caused cell, appears to be localized predominantly to the ER (17, 21), by mutations in members of the EXT gene family, EXT1 or EXT2. The whereas the biosynthesis of HS chains is thought to occur in the proteins encoded by these genes, EXT1 and EXT2, are endoplasmic Golgi cisternae (22–25). Moreover, if the EXT1 and EXT2 genes reticulum-localized type II transmembrane glycoproteins that pos- encode functionally redundant HS polymerases (HS-Pol), it is sess or are tightly associated with glycosyltransferase activities not clear why mutations in either gene cause HME. involved in the polymerization of heparan sulfate. Here, by testing To address these questions, we overexpressed functional a cell line with a specific defect in EXT1 in in vivo and in vitro assays, epitope-tagged and native forms of EXT1 and EXT2 in cells and we show that EXT2 does not harbor significant glycosyltransferase examined their subcellular localization and enzymatic activity. activity in the absence of EXT1. Instead, it appears that EXT1 and By using a cell line, sog9, with a specific defect in EXT1, we show EXT2 form a hetero-oligomeric complex in vivo that leads to the that EXT2 does not harbor significant glycosyltransferase activ- accumulation of both proteins in the Golgi apparatus.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub
    US 2003O19897OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0198970 A1 Roberts (43) Pub. Date: Oct. 23, 2003 (54) GENOSTICS clinical trials on groups or cohorts of patients. This group data is used to derive a Standardised method of treatment (75) Inventor: Gareth Wyn Roberts, Cambs (GB) which is Subsequently applied on an individual basis. There is considerable evidence that a significant factor underlying Correspondence Address: the individual variability in response to disease, therapy and FINNEGAN, HENDERSON, FARABOW, prognosis lies in a person's genetic make-up. There have GARRETT & DUNNER been numerous examples relating that polymorphisms LLP within a given gene can alter the functionality of the protein 1300 ISTREET, NW encoded by that gene thus leading to a variable physiological WASHINGTON, DC 20005 (US) response. In order to bring about the integration of genomics into medical practice and enable design and building of a (73) Assignee: GENOSTIC PHARMA LIMITED technology platform which will enable the everyday practice (21) Appl. No.: 10/206,568 of molecular medicine a way must be invented for the DNA Sequence data to be aligned with the identification of genes (22) Filed: Jul. 29, 2002 central to the induction, development, progression and out come of disease or physiological States of interest. Accord Related U.S. Application Data ing to the invention, the number of genes and their configu rations (mutations and polymorphisms) needed to be (63) Continuation of application No. 09/325,123, filed on identified in order to provide critical clinical information Jun. 3, 1999, now abandoned. concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome.
    [Show full text]